Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study
PR Newswire•03/11/2026•08:15 ET
0
Key Highlights
- ➤11,991 patients studied in largest real-world nonendoscopic esophageal precancer testing analysis
- ➤EsoCheck collection succeeded in 95% of patients, averaging under two minutes
- ➤Medicare now fully reimburses EsoGuard nationwide, supporting accelerated commercialization
- ➤96% would recommend EsoGuard testing; 95% would repeat it if indicated
Expert Statements
Lishan Aklog, M.D., Chairman and Chief Executive Officer of Lucid Diagnostics
“These findings provide compelling real-world evidence supporting the feasibility of large-scale implementation of EsoGuard testing.”
Lishan Aklog, M.D., Chairman and Chief Executive Officer of Lucid Diagnostics
“With EsoGuard now fully reimbursed by Medicare nationwide, efficient and scalable clinical implementation will be critical as we accelerate commercialization across diverse clinical settings in the coming months.”
Victoria T. Lee, M.D., Chief Medical Officer of Lucid Diagnostics
“We are very encouraged by the real-world performance of adveEsoGuard and EsoCheck in this large cohort of patients referred for esophageal precancer testing.”
Victoria T. Lee, M.D., Chief Medical Officer of Lucid Diagnostics
“The high cell collection success rate across operators, including among newly trained personnel, high patient satisfaction scores, and short average procedure time strongly support large-scale implementation to broadly expand access to esophageal precancer testing in at-risk patients.”
Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study PR Newswire
Largest peer-reviewed study of nonendoscopic esophageal precancer testing to date demonstrates the efficiency and scalability of EsoCheck(®) cell collection in under two minutes
Get started
Create a free account to read the full story.